Trial Profile
A phase III study of GSK 961081/fluticasone furoate to explore its potential as a once-daily medicine delivered in the ELLIPTA inhaler
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs Batefenterol/fluticasone furoate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- 06 May 2013 New trial record